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ABSTRACT
Introduction: Secukinumab and adalimumab are
approved for adults with active psoriatic arthritis
(PsA). In the absence of direct randomized
controlled trial (RCT) data, matching-adjusted
indirect comparison can estimate the comparative
effectiveness in anti-tumor necrosis factor (TNF)-
naı¨ve populations.
Methods: Individual patient data from the
FUTURE 2 RCT (secukinumab vs. placebo;
N = 299) were adjusted to match baseline char-
acteristics of the ADEPT RCT (adalimumab vs.
placebo; N = 313). Logistic regression deter-
mined adjustment weights for age, body weight,
sex, race, methotrexate use, psoriasis affect-
ing C 3% of body surface area, Psoriasis Area
and Severity Index score, Health Assessment
Questionnaire Disability Index score, presence
of dactylitis and enthesitis, and previous anti-
TNF therapy. Recalculated secukinumab out-
comes were compared with adalimumab out-
comes at weeks 12 (placebo-adjusted), 16, 24,
and 48 (nonplacebo-adjusted).
Results: After matching, the effective sample
size for FUTURE 2 was 101. Week 12 American
College of Rheumatology (ACR) response rates
were not significantly different between secuk-
inumab and adalimumab. Week 16 ACR 20 and
50 response rates were higher for secukinumab
150 mg than for adalimumab (P = 0.017,
P = 0.033), as was ACR 50 for secukinumab
300 mg (P = 0.030). Week 24 ACR 20 and 50
were higher for secukinumab 150 mg than for
adalimumab (P = 0.001, P = 0.019), as was ACR
20 for secukinumab 300 mg (P = 0.048). Week
48 ACR 20 was higher for secukinumab 150 and
300 mg than for adalimumab (P = 0.002,
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P = 0.027), as was ACR 50 for secukinumab
300 mg (P = 0.032).
Conclusions: In our analysis, patients with PsA
receiving secukinumab were more likely to
achieve higher ACR responses through 1 year
(weeks 16–48) than those treated with adali-
mumab. Although informative, these observa-
tions rely on a subgroup of patients from
FUTURE 2 and thus should be considered
interim until the ongoing head-to-head RCT
EXCEED can validate these findings.
Funding: Novartis Pharma AG.
Keywords: Adalimumab; Comparative
effectiveness; Matching-adjusted indirect
comparison; Psoriatic arthritis; Secukinumab
INTRODUCTION
For patients with active psoriatic arthritis (PsA),
international recommendations such as those
of the European League Against Rheumatism
(EULAR) [1, 2] and the Group for Research and
Assessment of Psoriasis and Psoriatic Arthritis
(GRAPPA) [3] advise the use of biologic disease-
modifying antirheumatic drugs (bDMARDs)
when a patient’s response to conventional
synthetic DMARDs (csDMARDs; bDMARD and
csDMARD defined according to EULAR) is
inadequate. Historically, bDMARDs have tar-
geted tumor necrosis factor (TNF) but now also
include antibodies targeting interleukin 12/23
and interleukin-17A (IL-17A) [4].
At least seven bDMARDs, mainly targeting
TNF, are now available for use in patients with
PsA. Thus, to help optimize treatment plans for
this long-term chronic condition, appropriately
powered head-to-head (H2H) randomized con-
trolled trials (RCTs) comparing the efficacy and
safety of different bDMARDs are required. One
such trial is EXCEED, directly comparing the
long-term (52 weeks) efficacy and safety of the
fully human anti-IL-17A secukinumab with the
anti-TNF adalimumab [5]. Until data from this
trial become available, clinicians and health
technology assessment bodies may need to
resort to adjusted indirect comparisons of these
medicines as the best available evidence to
inform treatment decisions.
One means of bridging this evidence gap is
through the use of inferential analyses such as
network meta-analysis [6, 7]. Such techniques
are useful when there is a common comparator
arm between RCTs (or in general a connected
network of studies [6]) and similar study popu-
lations, but the methodology is limited by fur-
ther cross-trial differences, potential lack of
common comparators (or connected networks),
sensitivity to modeling assumptions, and dis-
parities in definitions of outcome measures
[6, 7]. Matching-adjusted indirect comparison
(MAIC) incorporates individual patient data
(IPD) to address several of the limitations that
arise in comparisons based only on aggregate
data; thus, it can simulate more closely how
treatments may have performed if compared
directly [8–10].
MAIC uses IPD from one or multiple studies
for one treatment to match clinically relevant
baseline aggregate characteristics from a pub-
lished study of another treatment. The patient
characteristics from the IPD are adjusted, using
a frequently used form of propensity score
matching, so that the mean baseline character-
istics match those of the aggregate data. This
process results in a reduced effective sample size
(ESS) for the IPD arms. Outcomes from common
comparator arms such as placebo can be used to
validate the matching. After matching, the
mean of the recalculated matched IPD is com-
pared with the observed mean for the aggregate
data from the published study [8].
The results from MAIC in PsA and other
conditions have been reported in peer-reviewed
publications [11–13], and MAIC has been
acknowledged as a valid methodological tool by
health-technology assessment agencies [10, 14].
MAIC is evolving and becoming a useful com-
plementary technique to meta-analysis in pro-
viding comparative effectiveness evidence,
especially when such information is unavailable
from direct clinical trial comparisons [8]. MAIC
has previously been applied to assess the com-
parative effectiveness of adalimumab versus
etanercept [11] and adalimumab versus etaner-
cept or infliximab in patients with psoriasis and
PsA, respectively [13]. A short- to midterm
MAIC analysis (24 weeks) between adalimumab
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and secukinumab in patients with PsA was
recently published [12].
Our study sought to address the evidence gap
in the comparative effectiveness of up to 1 year
biologic treatment of IL-17A versus anti-TNF in
patients with PsA. Therefore, MAIC was used to
compare adalimumab and secukinumab based
on common primary and secondary outcome
measures from the ADEPT [15–17] and FUTURE
2 [18] trials.
METHODS
Systematic Literature Review
A systematic literature review (SLR) was con-
ducted in September 2014 and updated on
November 6, 2015 to identify all relevant clin-
ical evidence for the use of secukinumab and
relevant comparators in the treatment of adult
patients with PsA. This article is based on pre-
viously conducted studies and does not involve
any new studies of human or animal subjects.
The SLR eligibility criteria are outlined in
Table S1, and the Preferred Reporting Items for
Systematic Reviews and Meta-analyses
(PRISMA) flow chart is shown in Fig. S1, both in
the supplementary material. Following full-text
screening, 29 trials were suitable for inclusion
according to the eligibility criteria. For the
purpose of this analysis, adalimumab is con-
sidered the comparator of interest to secuk-
inumab, because of its equivalent efficacy to
other anti-TNFs and widespread clinical use
[19].
Of the 29 trials, 19 included neither secuk-
inumab nor adalimumab and were excluded
from this MAIC. The remaining ten studies are
shown in Table S2 in the supplementary mate-
rial with the reasons for exclusion. Of these ten
trials, six investigated secukinumab (CLEAR
[20], ERASURE [21], FUTURE 1 [22], FIXTURE
[21], FUTURE 2 [18], and McInnes et al. [23]),
and the remaining four studied adalimumab
(ADEPT [15], Behrens et al. [24], Genovese et al.
[25], and van Kuijk et al. [26]). Three of these
trials, CLEAR, ERASURE, and FIXTURE, were
then excluded because they included patients
with moderate-to-severe psoriasis, of whom
only a subgroup had concomitant PsA. The
study by Behrens et al. [24] was excluded
because it was an observational study. Genovese
et al. [25] was excluded because the randomized
placebo-controlled stage lasted only until week
12, and McInnes et al. [23] was excluded
because it was a phase 2 study. Van Kuijk et al.
[26] was excluded because the study was
restricted to synovial biopsy analyses. Finally,
the phase 3 study FUTURE 1 [22] was excluded
because only one of two licensed subcutaneous
maintenance doses of secukinumab was inves-
tigated (150 mg) and it used an intravenous
loading method.
Source Data
FUTURE 2 (NCT01752634) was a phase 3,
double-blind RCT in adults with active PsA
(Fig. 1) [18, 27–29]. Patients were randomized to
subcutaneous secukinumab (300, 150, or
75 mg) or placebo, once per week from baseline
to week 4 and every 4 weeks thereafter [18]. The
primary endpoint was the proportion of
patients achieving a 20% or greater improve-
ment in the American College of Rheumatology
(ACR 20) response criteria at week 24 [30].
Patients receiving concomitant corticosteroid or
methotrexate (MTX) medication or who had a
previous inadequate response or inability to
tolerate up to three different anti-TNF therapies
(anti-TNF-IR) could enroll. These biologic-
experienced patients made up 35% of the total
study population. At week 16, patients were
assessed as either responders (C 20% improve-
ment from baseline in swollen and tender joint
counts) or nonresponders. Placebo-treated
patients were rerandomized in a 1:1 ratio to
secukinumab 150 or 300 mg every 4 weeks from
week 16 (nonresponders) and week 24
(responders).
ADEPT was a phase 3, double-blind RCT in
adults with active PsA (Fig. 1) [15]. Patients were
randomized to receive subcutaneous adali-
mumab 40 mg or placebo every other week. The
primary endpoints were the proportion of
patients achieving an ACR 20 response at
week 12 and the change in modified total Sharp
score of structural damage on radiographs of the
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hands and feet at week 24. Patients could enroll
if they were receiving concomitant MTX medi-
cation as long as the dose was stable for at least
3 months and was not higher than 30 mg per
week. Patients who had previously used any
form of anti-TNF biologic were excluded. After
Fig. 1 FUTURE 2 and ADEPT trial designs relative to
MAIC analysis. aPatients who had a C 20% improvement
compared with baseline in TJC and SJC. bPatients who
had a\ 20% improvement compared with baseline in
TJC and SJC. c153 patients were randomized; however,
two patients were not given adalimumab. Analyses were
performed on 151 patients who received adalimumab.
dPatients who completed the 24-week double-blind period
were eligible for the open-label extension study (adali-
mumab 40 mg EOW). Patients who failed to demonstrate
a C 20% improvement compared with baseline in TJC
and SJC (study week 36) were allowed to increase the
adalimumab dosage to 40 mg weekly. ePatients who did
not demonstrate a C 20% improvement compared with
baseline in ACR 20 could receive rescue therapy (corti-
costeroids and/or csDMARDs). The time points (weeks
from ﬁrst subcutaneous injection) at which postmatching
outcome comparisons were made are indicated. ACR
outcomes were compared at week 12 (placebo-adjusted)
and at weeks 16, 24, and 48/52 (nonplacebo-adjusted).
The placebo-adjusted phase comparison was valid only
until week 12 (shown by yellow rectangle) because of the
rescue therapy design component of ADEPT. Numbers in
gray denote the ITT populations. All FUTURE 2
secukinumab outcomes were ITT to week 52. ADEPT
adalimumab ITT outcome data were maintained until
week 48 using published data [16]. Open-label extension
adalimumab week 36 dose increase to weekly adalimumab
(n = 15 and n = 23 in the original adalimumab and
placebo groups, respectively) was classiﬁed as NRI. ACR
American College of Rheumatology, csDMARD conven-
tional synthetic DMARD, DMARD disease-modifying
antirheumatic drug, EOW every other week, ITT intent-
to-treat, MAIC matching-adjusted indirect comparison,
mTSS modiﬁed total Sharp score, NRI nonresponder
imputation, R randomization, SJC swollen joint count,
TJC tender joint count
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week 12, patients whose swollen and tender
joint counts did not decrease by at least 20% on
two consecutive visits could receive rescue
therapy with corticosteroids or csDMARDs [15].
All patients who completed the initial 24 weeks
of treatment were eligible to receive adali-
mumab 40 mg as part of an open-label exten-
sion study [15, 16].
MAIC Methodology
The MAIC methodology is graphically summa-
rized in Fig. 2.
Selection of Baseline Characteristics
for Matching
Matching variables were selected for their
potential influence on key efficacy outcomes on
joints and skin; there was no specific matching
for baseline safety parameters. The clinical rele-
vance of potential matching variables was dis-
cussed among the authors, who include clinical
experts in the treatment of active PsA, as well as
health economics and comparative effectiveness
research experts. In addition, correlation analy-
ses of patient baseline characteristics with ACR
20, 50, and 70 responses achieved at week 48 in
FUTURE 2 informed the choice of matching
variables (Tables S3–S5 in the supplementary
material). This strategy is in line with a recent
National Institute for Health and Care Excel-
lence (NICE) guidance on MAIC methodology
(NICE Decision Support Unit technical support
document 18 [NICE DSU TSD 18]) [10], which
recommends justifying the choice of matching
parameter by clinical expert advice and/or
empirical identification of all prognostic vari-
ables and effect modifiers in the weighting
model (depending on whether anchored [all
effect modifiers] or unanchored [all effect mod-
ifiers and prognostic variables] comparisons are
being made). Although NICE is geared to a UK
payer perspective, its MAIC guidelines were
constructed by a group of globally acknowl-
edged academic experts in comparative statistics
and represent the only methodologically
advanced guidelines published to date.
Two scenarios were developed that differed
in the combination of matching variables
included. First, a principal analysis replicated
the baseline characteristics of a previous MAIC
between the same two trials [12], including
established prognostic variables, but updated to
include parameters identified by logistic
regression analysis as having the greatest impact
on ACR criteria outcomes (prognostic variables
or effect modifiers). One additional baseline
parameter, biologic-experienced (i.e., previous
inadequate response or intolerance to anti-TNF
exposure), was identified as a key variable to
have an impact on responses (ACR 20 odds ratio
[95% confidence interval (CI)], 0.431 [0.265,
0.701]; P = 0.0007) and therefore included in
the principal analysis (Table 1). Similarly, data
from the trial ACCLAIM, an open-label study,
have shown that patients previously exposed to
a biologic therapy have a lower response with
adalimumab than those who are biologic-naı¨ve
[31]. The sensitivity analysis (Table S6 in the
supplementary material) used a more compre-
hensive set of matching variables and included
all of those used in the principal analysis plus
three more clinically relevant baseline charac-
teristics to increase the matching stringency:
PsA disease duration (time since diagnosis),
swollen joint count (SJC), and C-reactive pro-
tein (CRP) levels.
Matching and Adjusting IPD to Published
Aggregate Data
IPD from the pooled secukinumab arms of the
FUTURE 2 trial (75, 150, and 300 mg) were
weighted to match the selected patient baseline
characteristics for the adalimumab arm of
ADEPT. The adalimumab data were reported
aggregates taken from the trial publications.
Only secukinumab 150 and 300 mg outcomes
were compared with adalimumab outcomes
because these are the doses licensed in PsA. The
methodology was based on Signorovitch et al.
[11], subsequent studies [8, 13, 32], and NICE
DSU TSD 18 [9, 10]. SAS version 9.4 and R ver-
sion 3.2.1 were used for the analysis. The
regression results were used to weight patients
in FUTURE 2, using the method of moments
(mean only) so that each patient’s weight cor-
responded to his or her relative propensity for
enrolling in FUTURE 2 versus ADEPT. After this
matching process, the weighted mean baseline
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Fig. 2 MAIC methodology using a hypothetical example.
Two treatments of interest have been identiﬁed (by SLR):
one treatment is examined in study A and another
treatment in study B. The researcher has access to IPD for
study B but only aggregate published data for study A. Step
1: relevant clinical baseline parameters are selected for
matching following consultation with clinical and statis-
tical experts. Step 2: the similarity of IPD baseline
characteristics with those of the aggregate study A
characteristics (color-coded in this example: red, high
through to green, low) will dictate how inﬂuential that
IPD will be within the matching process. Step 3: matching
is performed by application of weights to each IPD
(derived by logistic regression) using a matching algorithm
similar to propensity score matching. The method of
moment was applied using the quasi-Newton optimization
‘‘BFGS’’ implemented in the R function optim, as
recommended [9, 10]. IPD with a closer match to the
aggregate study A baseline characteristics are ‘‘upweighted,’’
while those with a poor match are ‘‘downweighted.’’ In this
example, this leads to an ESS of 4 (rounded to the nearest
integer to avoid confusion) using the equation shown. Step
4: study B mean IPD population baseline characteristics
match the mean of study A and outcomes can now be
compared directly between the two studies. The same
weights are used to recalculate each IPD outcome, and
then the mean recalculated study B IPD outcomes are
directly compared with the published aggregate study A
outcomes using appropriate statistical tests. aSome IPD
when highly incompatible with the target trial population
are given weights that are extremely small (weighting is on
a quantitative scale) and effectively act as a zero weight.
ESS effective sample size, IPD individual patient data,
MAIC matching-adjusted indirect comparison, SLR sys-
tematic literature review
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characteristics of the FUTURE 2 population
matched those reported for ADEPT, and the
sample size of FUTURE 2 was reduced to a lower
ESS.
Comparing Outcomes Using Recalculated
Patient Data
The weights were used to recalculate outcomes
for each IPD, and these were used to estimate
the comparative effectiveness of secukinumab
and adalimumab [8].
Analyses
Missing Data Handing
In ADEPT, all published outcomes were from
the intention-to-treat (ITT) population. All
missing binary outcome data (ACR 20, 50, and
70) were handled using nonresponder imputa-
tion (NRI) [15, 16], while missing patient-re-
ported outcomes (PROs; continuous) were
handled using last observation carried forward
(LOCF) methodology. In FUTURE 2 [18], out-
comes were from the ITT population. All miss-
ing binary outcome data (ACR 20, 50, and 70)
were derived using NRI, while all missing PRO
data (continuous) were derived using LOCF to
match the available data from ADEPT. It is
worth highlighting that our analysis did not use
penalties at week 24 for early non-responders,
thereby removing ‘bias’ when comparing our
results with those for adalimumab and making
our approach different from the numbers
reported in the main FUTURE 2 publications.
Outcomes
Outcomes selected for comparison were in line
with the Outcomes Measures in Rheumatology
(OMERACT) [33, 34] and GRAPPA [35] recom-
mendations on outcome measures that should
be included in PsA clinical trials [33, 34].
• ACR response rates: ACR 20, 50, and 70
response rates were assessed at weeks 12, 16,
24, and 48 in both trials.
• PRO scores: mean change from baseline in
Health Assessment Questionnaire Disability
Index (HAQ-DI), Patient Global Assessment
(PGA), pain assessment, and the Functional
Assessment of Chronic Illness Therapy-
Fatigue (FACIT-F) score were included. Out-
comes were reported at weeks 12, 24, and 48
in ADEPT so comparisons were feasible at
these time points; no data were available for
week 16 in ADEPT.
Placebo-Adjusted and Nonplacebo-Adjusted
Outcome Comparisons
The study designs of the trials (Fig. 1) specified
that patients randomized to placebo could
receive active treatment from week 16 in
FUTURE 2 or rescue therapy (corticosteroids or
csDMARDs) from week 12 in ADEPT; hence,
unbiased placebo-adjusted treatment compar-
isons were not possible after week 12. After week
12, outcomes from the adalimumab arm in
ADEPT were directly compared with outcomes
from the recalculated secukinumab arm of
FUTURE 2. This is similar to a comparison of
outcomes of two single-arm trials. In these sit-
uations, the use of MAIC may be the only way
to adjust for cross-trial differences and should
be preferred over naı¨ve unadjusted compar-
isons. Commonly used in observational studies
[36], this approach has been successfully
applied to previous MAIC analyses of RCTs,
such as when placebo comparisons were not
available or valid [37], to overcome placebo
crossover, or extrapolation beyond study end
[32, 38].
A week 12, placebo-adjusted comparison was
also made. In addition to providing meaningful
short-term placebo-adjusted data, the placebo
arms also act as a form of matching control,
because if the populations have been properly
matched (assuming no variables that impact on
placebo responses that cannot be controlled
through matching), there should be limited
cross-trial differences in placebo arm responses.
Pairwise Comparisons
For ACR outcomes, relative risk (RR; see Fig. S2
in the supplementary material) values were
estimated as the ratio of response rates (Table S7
in the supplementary material), and P values
(two-sided) for indirect treatment comparison
using RR were derived from the corresponding
Z-statistic. For placebo-adjusted comparisons,
RRs and corresponding standard errors were
Rheumatol Ther (2018) 5:99–122 105
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calculated using the Bucher method [7]. Odds
ratios (ORs; see Fig. S2 in the supplementary
material) were also calculated for ACR responses
(Table S7 in the supplementary material). The
commonly used threshold of P\ 0.05 was
considered as a threshold for statistical signifi-
cance (i.e., the incompatibility of observed data
with the null hypothesis position that there is
no difference between secukinumab and adali-
mumab for the outcome being compared). In
acknowledgment of the recent American Sta-
tistical Association statement on P values and
their preference to avoid such a threshold in
clinical research [39, 40], our data were also
analyzed using a more modern definition of the
strength of evidence that P values can provide
[41, 42] (0.1[P\0.001 as increasing evidence,
P B 0.001 as strong evidence against the null
hypothesis; Table S8 in the supplementary
material). For nonplacebo-adjusted compar-
isons, standard errors for RR values were esti-
mated based on the information provided by a
fictitious 2 9 2 contingency table that shows
outcomes in the adalimumab arm of the ADEPT
trial and outcomes in the recalculated secuk-
inumab arm of FUTURE 2 (with the ESS used as
the sample size for FUTURE 2). For the analysis
at week 12 (placebo-adjusted), RRs (and ORs) for
the secukinumab arm versus the placebo arm in
the reweighted FUTURE 2 population were
derived from a logistic regression model by
using generalized estimating equations with
robust standard errors as suggested in previous
work [9–11]. Generalized estimating equations
were fitted using PROC GENMOD in SAS.
For PRO scores, a 95% CI around mean
change scores of patients in the adalimumab
arm of the ADEPT trial was estimated using the
normal approximation. The P values for the
difference in mean change scores between
secukinumab and adalimumab were calculated
using a Z-statistic that divides the difference in
mean change scores by the combined standard
error.
Psoriasis Area and Severity Index Outcomes
We did not report comparative Psoriasis Area
and Severity Index (PASI) data, as the baseline
characteristic data for the ADEPT trial psoriasis
subgroup were not available. This meant that
uncontrolled imbalances could persist post-
matching. Indeed, the high absolute differences
in PASI at baseline between studies lend further
weight to this limitation. It is also worth noting
that PASI outcome data were collected only in a
subgroup of patients in both studies (patients
with psoriasis affecting C 3% body surface
area), thus missing data in the non-PASI-mat-
ched population will further compound this
study bias.
Methotrexate Subgroup Analysis
The long-term efficacy of anti-TNFs has been
linked to concomitant MTX use [43]. MTX
prescribed in combination with an anti-TNF
may prolong anti-TNF survival [44] and dampen
the generation of neutralizing antibodies to
anti-TNFs [45–48]. Data from clinical registry
studies suggest that the role of MTX in pro-
moting persistence varies between different
anti-TNFs [49].
Therefore, the impact of concomitant MTX
on IL-17A versus anti-TNF treatment was asses-
sed by a subgroup analysis in which patients
were divided by concomitant MTX use at base-
line. The issues surrounding the PASI data
(above) do not affect the MTX subgroup analy-
sis, as these data were collected for all patients
(recorded as receiving or not receiving con-
comitant MTX) at the included timepoints.
RESULTS
Principal Analysis
Matching Baseline Characteristics
Table 1 shows the baseline characteristics of
patients from the FUTURE 2 secukinumab
(pooled 75, 150, and 300 mg arms, n = 299
before matching) and placebo (n = 98 before
matching) arms before and after matching
(150 and 300 mg only [75 mg was not used in
this comparison] and placebo) to the ADEPT
adalimumab (n = 151) and placebo (n = 162)
arms. Before matching, the study populations of
FUTURE 2 and ADEPT were heterogeneous with
FUTURE 2 including more difficult-to-treat
patients. One of the key differences between the
patient populations was that patients treated
108 Rheumatol Ther (2018) 5:99–122
with secukinumab were either anti-TNF-naı¨ve
(65.2%) or anti-TNF-IR (34.8%), whereas all
patients treated with adalimumab were anti-
TNF-naı¨ve (100%). After matching IPD from
FUTURE 2 to ADEPT, all patients treated with
secukinumab (or placebo) were anti-TNF-naı¨ve
(100%). Another key prematch dissimilarity
between trials was baseline PASI score and a
more severe HAQ-DI, indicating higher func-
tional disability of the patient population in
FUTURE 2.
Achieving homogeneity between the two
populations reduced the sample size; the ESSs
for FUTURE 2 after matching were 36
Fig. 3 ACR comparisons: principal analysis. P values are derived from relative risk values. Error bars show 95% conﬁdence
intervals. Numbers above bars are the absolute mean predicted responses (ADEPT) and the predicted mean responses
(FUTURE 2). Yellow background indicates that comparison was placebo-adjusted, white background indicates that
comparison was nonplacebo-adjusted. ACR 20/50/70 20%/50%/70% or greater improvement in the American College of
Rheumatology response criteria, ADA adalimumab, ESS effective sample size, SEC secukinumab
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Table 2 Comparison of principal and sensitivity analyses (relative risks)
Principal analysis (SEC vs. ADA) Sensitivity analysis (SEC vs. ADA)
ADA 40 mg, n = 151; PBO, n = 162 ADA 40 mg, n = 151; PBO, n = 162
SEC 150 mg, ESS = 36; PBO, ESS = 27 SEC 150 mg, ESS = 15; PBO, ESS = 20
SEC 300 mg, ESS = 38; PBO, ESS = 27 SEC 300 mg, ESS = 25; PBO, ESS = 20
ACR 20 ACR 50 ACR 70 ACR 20 ACR 50 ACR 70
Week 12, placebo-adjusted data (SEC 150 mg)
0.69 (0.34, 1.43) 0.91 (0.23, 3.60) 0.68 (0.07, 6.22) 1.06 (0.39, 2.92) 10.44 (1.80, 60.56)
P = 0.009
5.99 (0.56, 63.79)
Week 12, placebo-adjusted data (SEC 300 mg)
0.61 (0.29, 1.27) 0.97 (0.25, 3.79) 0.50 (0.05, 4.93) 0.94 (0.34, 2.61) 16.01 (2.95, 86.84)
P = 0.001
6.85 (0.64, 73.92)
Week 16 (SEC 150 mg)
1.34 (1.05, 1.70)
P = 0.017
1.54 (1.03, 2.30)
P = 0.033
0.90 (0.43, 1.92) 1.44 (1.08, 1.92)
P = 0.014
1.67 (0.99, 2.80)
P = 0.055
0.91 (0.30, 2.73)
Week 16 (SEC 300 mg)
1.18 (0.90, 1.54) 1.54 (1.04, 2.29)
P = 0.030
0.91 (0.44, 1.89) 1.35 (1.03, 1.76)
P = 0.030
1.63 (1.05, 2.52)
P = 0.029
0.92 (0.39, 2.20)
Week 24 (SEC 150 mg)
1.42 (1.15, 1.75)
P = 0.001
1.50 (1.07, 2.10)
P = 0.019
1.59 (0.95, 2.67) 1.46 (1.12, 1.91)
P = 0.005
1.52 (0.96, 2.42) 1.54 (0.74, 3.23)
Week 24 (SEC 300 mg)
1.27 (1.00, 1.62)
P = 0.048
1.05 (0.69, 1.62) 0.99 (0.52, 1.90) 1.40 (1.10, 1.78)
P = 0.006
1.08 (0.66, 1.79) 1.00 (0.47, 2.17)
Week 48 (SEC 150 mg)
1.41 (1.14, 1.76)
P = 0.002
1.31 (0.93, 1.83) 1.09 (0.64, 1.85) 1.41 (1.05, 1.89)
P = 0.022
1.55 (1.04, 2.30)
P = 0.029
1.29 (0.65, 2.56)
Week 48 (SEC 300 mg)
1.31 (1.03, 1.66)
P = 0.027
1.41 (1.03, 1.92)
P = 0.032
1.44 (0.93, 2.24) 1.45 (1.15, 1.83)
P = 0.002
1.66 (1.23, 2.24)
P < 0.001
1.68 (1.05, 2.66)
P = 0.029
Data are shown as relative risk (95% conﬁdence interval)
P values (bold text when signiﬁcant, i.e., P\ 0.05) were derived from relative risk values using the Z-statistic. All statistically
signiﬁcant observations made were in favor of SEC compared with ADA. No signiﬁcantly higher outcomes for ADA
compared with SEC were observed
ACR 20/50/70 20%/50%/70% or greater improvement in the American College of Rheumatology response criteria, ADA
adalimumab, ESS effective sample size, PBO placebo, SEC secukinumab
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(secukinumab 150 mg), 38 (secukinumab
300 mg), and 27 (placebo).
It has been proposed that outcomes from
common comparator arms such as placebo can
be used to validate the matching process, i.e., a
good match should lead to equivalent or near-
equivalent placebo arm responses [8, 50]. Pla-
cebo arm ACR 20 (week 12) responses were
14.2% (ADEPT) and 26.7% (FUTURE 2); ACR 50
responses were 3.7% (ADEPT) and 4.3%
(FUTURE 2). Given that ACR 50 is a significantly
more stringent outcome than ACR 20, the near
equivalence of the placebo response between
ADEPT and recalculated FUTURE 2 suggests a
good match.
ACR Response Rates
Figure 3 and Table 2 show the ACR 20, 50, and
70 response rates in the principal analysis. At
week 12, there were no statistically significant
differences in any ACR placebo-adjusted
response rates between secukinumab and adal-
imumab. Week 16 ACR 20 and 50 response rates
were significantly higher for secukinumab
150 mg than for adalimumab [RR, 1.34 (95% CI:
1.05, 1.70); P = 0.017 and RR, 1.54 (95% CI:
1.03, 2.30); P = 0.033, respectively], as was the
ACR 50 response rate for secukinumab 300 mg
over adalimumab [RR, 1.54 (95% CI: 1.04, 2.29);
P = 0.030]. Week 24 ACR 20 and 50 response
rates were significantly higher for secukinumab
Fig. 4 Methotrexate subgroup analysis: MAIC-predicted
ACR response rates at weeks 24 and 48 in patients
(a) receiving and (b) not receiving methotrexate at
baseline. P values are derived from RR values. Error bars
show 95% conﬁdence intervals. Numbers above bars show
the absolute mean predicted responses (ADEPT) and the
predicted mean responses (FUTURE 2). ACR 20/50/70
20%/50%/70% or greater improvement in the American
College of Rheumatology response criteria, ADA adali-
mumab, ESS effective sample size, MAIC matching-
adjusted indirect comparison, RR relative risk, SEC
secukinumab
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150 mg than for adalimumab [RR, 1.42 (95% CI:
1.15, 1.75); P = 0.001 and RR, 1.50 (95% CI:
1.07, 2.10); P = 0.019, respectively], as was the
ACR 20 response rate for secukinumab 300 mg
over adalimumab [RR, 1.27 (95% CI: 1.00, 1.62);
P = 0.048]. The week 48 ACR 20 response rate
was significantly higher for secukinumab
150 mg than for adalimumab [RR, 1.41 (95% CI:
1.14, 1.76); P = 0.002], as were the ACR 20 and
50 response rates for secukinumab 300 mg over
adalimumab [RR, 1.31 (95% CI: 1.03, 1.66);
P = 0.027 and RR, 1.41 (95% CI: 1.03, 1.92);
P = 0.032, respectively].
PRO Scores
Table 3 shows the principal analysis comparison
of HAQ-DI, PGA, pain assessment, and FACIT-F
scores. At week 12, there were no significant
differences in any continuous outcome data
between secukinumab and adalimumab. No
ADEPT data were available for week 16. At week
24, treatment with secukinumab 150 mg resul-
ted in significantly greater improvements in
HAQ-DI, PGA, and pain scores relative to adal-
imumab (– 0.53 vs. – 0.40, P = 0.046; – 30.2 vs.
– 21.1, P = 0.005; and – 30.4 vs. – 24.0,
P = 0.039, respectively). Adalimumab therapy
resulted in a significantly greater improvement
in FACIT-F score relative to secukinumab
300 mg (7.1 vs. 4.5, P = 0.021), although there
was no difference relative to secukinumab
150 mg. At week 48, treatment with secuk-
inumab 150 mg resulted in a significantly
greater improvement in HAQ-DI score, while
secukinumab 300 mg had a significantly greater
improvement in PGA score relative to adali-
mumab (– 0.54 vs. – 0.40, P = 0.037 and – 29.4
vs. – 22.4, P = 0.016, respectively).
Methotrexate Subgroup Analysis
Concomitant MTX subgroup data from ADEPT
were available only at weeks 24 and 48. After
matching, the sample sizes at week 24 for the
subgroup receiving MTX (at baseline) were:
adalimumab, n = 77; secukinumab 150 mg,
ESS = 19; and secukinumab 300 mg, ESS = 17,
while the sample sizes for the subgroup not
receiving MTX (at baseline) were: ADEPT,
n = 74; secukinumab 150 mg, ESS = 17; and
secukinumab 300 mg, ESS = 22.
Figure 4 and Table 4 show the ACR response
rates for the principal analysis MTX subgroup
comparison. At week 24, for patients receiving
MTX at baseline, ACR 20 response rates were
higher with secukinumab 150 mg [RR, 1.55
(95% CI: 1.18, 2.05); P = 0.002] than with
adalimumab. For patients not receiving MTX at
baseline, ACR 20 response rates were higher
with secukinumab 300 mg than with adali-
mumab [RR, 1.33 (95% CI: 1.00, 1.77);
P = 0.048]. At week 48, for patients receiving
MTX at baseline, ACR 20 response rates were
higher with secukinumab 150 mg [RR, 1.37
(95% CI: 1.06, 1.76); P = 0.015] than with
adalimumab. For patients not receiving MTX at
baseline, ACR 20 [RR, 1.53 (95% CI: 1.11, 2.11);
P = 0.010], ACR 50 [RR, 1.78 (95% CI: 1.18,
2.67); P = 0.006] and ACR 70 [RR, 1.88 (95% CI:
1.12, 3.17); P = 0.017] response rates were
higher with secukinumab 300 mg than with
adalimumab.
Sensitivity Analysis
Matching Baseline Characteristics
The sensitivity analysis matched for the same
parameters as the principal analysis, with the
addition of three variables (PsA disease dura-
tion, SJC, and CRP), as shown in Table S6 in the
supplementary material. The ESSs in FUTURE 2
after matching were 15 (secukinumab 150 mg),
25 (secukinumab 300 mg), and 20 (placebo).
Placebo arm ACR 20 (week 12) response rates
were 14.2% (ADEPT) and 19.3% (secukinumab
150 mg, FUTURE 2); and ACR 50 responses were
3.7% (ADEPT) and 0.3% (FUTURE 2). The ACR
20 data suggest that this match was even closer
than that of the principal analysis. There
appears to be a lower ACR 50 placebo response
with secukinumab 150 mg relative to adali-
mumab, although the low ESS and low values
suggest this is a less reliable observation than
the ACR 20 comparison.
ACR Response Rates
Results were broadly consistent with those of
the principal analysis (Table 2), in that ACR 20
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and 50 response rates were significantly higher
for at least one secukinumab dose than for
adalimumab at weeks 16, 24, and 48. In addi-
tion, at the week-12 placebo-adjusted time
point, both doses of secukinumab showed a
significantly higher probability of achieving an
ACR 50 response than adalimumab.
PRO Scores
The sensitivity analysis also confirmed the
higher outcomes for secukinumab over adali-
mumab in HAQ-DI, PGA, and pain scores, as
seen in the principal analysis. In addition, week-
12 placebo-adjusted secukinumab 300 mg
showed a significantly greater improvement in
HAQ-DI scores from baseline, and there was no
longer any sign of higher outcomes for adali-
mumab in any of the FACIT-F scores (Table S9
in the supplementary material).
Methotrexate Subgroup Analysis
As shown in Table 4, the results were consistent
with the principal analysis. A consistent statis-
tically significantly higher probability of ACR
20 response rates was seen with secukinumab,
relative to adalimumab, at weeks 24 and 48
(nonplacebo-adjusted).
DISCUSSION
Our study used a methodologically valid MAIC
[10, 51] to assess the comparative effectiveness
of secukinumab versus adalimumab in patients
with active PsA. Although several indirect
comparison methodologies exist, MAIC was
chosen because it allows for a greater degree of
adjustment for cross-trial population differences
than analyses that use only aggregate data.
When populations are well matched [8], it is
possible to compare long-term data beyond the
placebo-controlled phase. This is necessary for
chronic conditions such as PsA because the
short-term placebo-controlled phase of most
RCTs provides only limited data to inform the
mid- to long-term treatment choices; indeed,
several oncology studies have applied MAIC
successfully to long-term patient survival data
[37, 38].
In the absence of H2H RCT data, MAIC is a
useful surrogate method that is, relative to an
RCT, faster, cheaper, and capable of providing
timely comparative evidence to relevant stake-
holders. Nevertheless, observational data gen-
erated by MAIC should be viewed as interim to
the reporting of a ‘‘gold-standard’’ H2H RCT,
such as the ongoing EXCEED trial [5].
Our study included both binary (ACR 20, 50,
and 70) and continuous (PRO scores) outcomes
in line with the OMERACT and GRAPPA rec-
ommendations [33, 34]. The choice of matching
variables was finalized after consultation with
clinical experts in the spondyloarthritides and
statistical fields, supplemented with empirical
data identifying key effect-modifying variables
[10]. Further baseline characteristics considered
potentially clinically relevant were included in
a sensitivity analysis. We selected adalimumab
as the comparator because of its equivalent
efficacy to other anti-TNFs and widespread
clinical use [19]. Anti-TNFs are established and
recommended treatment options for active PsA
[52–55]. Although there have been no H2H
RCTs between them, indirect retrospective data
suggest that they have similar efficacy and
safety profiles [55, 56]. Meta-analyses have
repeatedly shown no real differences in terms of
ACR outcomes among anti-TNFs [54, 57–60].
Our MAIC indicated that patients treated
with secukinumab had at least an equivalent, or
greater likelihood (depending on time point
and outcome) of experiencing an improvement
in joint signs and symptoms than individuals
treated with adalimumab. In the principal
analysis, both bDMARDs had comparable ACR
responses at week 12 (placebo-adjusted), whilst
we observed several statistically significant
higher responses for secukinumab from week 16
onwards using a nonplacebo-adjusted compari-
son. The strongest evidence supporting a higher
ACR response with secukinumab was apparent
at weeks 24 and 48 for the 150-mg dose. The
sensitivity analysis replicated the findings of the
principal analysis. Taken together, our analyses
provide a consistent body of evidence suggest-
ing that patients with active PsA treated with
secukinumab (150 or 300 mg) are more likely to
achieve an ACR response through 1 year (weeks
16–48).
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In the principal analysis of PRO data, we
observed significantly improved week-24 HAQ-
DI, PGA, and pain assessments and week-48
HAQ-DI scores for patients treated with secuk-
inumab 150 mg, and a significantly improved
PGA score for secukinumab 300 mg relative to
those treated with adalimumab. Improvement
in pain is considered by PsA patients to be the
most important domain [61]. The improve-
ments estimated for patients treated with
secukinumab 300 mg were similar to those for
individuals treated with adalimumab, for all
time points and all PRO scores, except PGA.
In both of our concomitant MTX subgroups,
we observed that patients receiving secuk-
inumab had a greater likelihood of experiencing
an improvement in joint signs and symptoms,
measured by ACR response criteria at weeks 24
and 48, than did individuals treated with adal-
imumab. These findings, confirmed by the
sensitivity analysis, suggest that the higher
long-term outcomes for secukinumab compared
with adalimumab for ACR response are inde-
pendent of MTX use. However, as separate
baseline matching was not performed in sub-
groups defined by MTX use, we cannot exclude
the possibility that these populations may differ
between the treatment groups.
The data reported in our study differ from a
recently published MAIC analysis that com-
pared IPD of the ADEPT trial with pooled
FUTURE 1 and 2 data [12]. Their primary anal-
ysis showed no statistically significant differ-
ences in ACR responses between secukinumab
and adalimumab at week 24 (placebo-adjusted)
[12]. However, there are five major method-
ological limitations in this analysis. First, the
matching parameters did not include previous
anti-TNF exposure, the single most important
observable baseline parameter. This is shown by
regression analysis (Table S4 in the supplemen-
tary material), by anti-TNF IR subgroup analysis
of FUTURE 2 [62], and by an earlier analysis of
adalimumab [31]. Second, the analysis was
based on a placebo-adjusted outcome compar-
ison at week 24. This may lead to bias [9, 63]
because by week 24, the respective placebo arms
of both studies had undergone significant pop-
ulation loss at cumulatively unequal rates as a
consequence of different study designs (Fig. 1).
Third, we consider the use of pooled FUTURE 1
and FUTURE 2 study aggregate data a ques-
tionable strategy for short-term comparisons
owing to their differences in loading adminis-
tration. Fourth, PASI comparisons were made
without being able to match the PASI patient
subgroup. For the same reasons, we opted not to
report PASI outcomes in this publication, as
described in the Methods section above. Fifth,
the other MAIC analysis did not use a linear
predictor scale, for instance ORs or RRs, which is
recommended by MAIC methodology guideli-
nes [10]. Overall, our study goes beyond the
scope of the previously published MAIC [12] in
two main aspects: by providing comparative
effectiveness data for up to 1 year at multiple
time points and for multiple clinical endpoints
and PROs, and by adjusting for previous anti-
TNF exposure. Despite the above-mentioned
limitations, the results reported in the sensitiv-
ity analysis of the previously published MAIC
[12] showed the same trend and are in agree-
ment with our study, i.e., higher ACR 20 and 50
outcomes in anti-TNF-naı¨ve patients receiving
secukinumab compared with adalimumab.
Moreover, two recent publications indicate
favorable sustainability and safety data for
secukinumab [27, 64].
Our MAIC has limitations, both intrinsic to
the methodology and specific to this analysis.
Although observed patient variables at baseline
can be matched, it is not possible to control for
unobserved or unreported variables. Although
both studies were not contemporaneous, a
common issue in comparative analysis, we have
made significant efforts to accommodate dif-
ferences in study design such as our matching of
appropriate missing data-handling and impu-
tation methods. More specific to our study, the
relatively small ESS used in all of the analyses,
driven by limited overlap between trial popu-
lations, must be taken into account when
interpreting our findings. A majority of the
FUTURE 2 patients were effectively lost after
matching (particularly in the sensitivity and
MTX subgroup analyses), and as such, the
findings of this MAIC rely upon a subset of trial
participants. Finally, due to differences in the
study trials regarding the time point from
which placebo-treated patients can receive
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rescue therapy, an unbiased placebo-adjustment
was not possible after week 12. Therefore, we
present nonplacebo-adjusted comparisons that,
while providing a legitimate means to compare
long-term data, do not permit adjustment for
unobserved differences in trial populations or
study design. Given these limitations, our MAIC
analysis is strongest during the placebo-
matched period, is hypothesis-generating only,
and needs to be confirmed via the ongoing
EXCEED H2H RCT of secukinumab versus
adalimumab in patients with active PsA.
CONCLUSIONS
This MAIC showed evidence suggesting that
patients with active PsA treated with secuk-
inumab and matched to the ADEPT study pop-
ulation have a significantly higher probability
of achieving ACR 20 and 50 response rates
through 1 year than those receiving adali-
mumab, an effect that appears to be indepen-
dent of concomitant MTX medication. To
substantiate these hypothesis-generating
interim findings, the next level of evidence will
be determined by the ongoing H2H RCT
EXCEED [5].
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